Literature DB >> 10942040

Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical relevance.

E X Albuquerque1, E F Pereira, A Mike, H M Eisenberg, A Maelicke, M Alkondon.   

Abstract

The present report describes the participation of nicotinic receptors (nAChRs) in controlling the excitability of local neuronal circuitries in the rat hippocampus and in the human cerebral cortex. The patch-clamp technique was used to record responses triggered by the non-selective agonist ACh and the alpha7-nAChR-selective agonist choline in interneurons of human cerebral cortical and rat hippocampal slices. Evidence is provided that functional alpha7- and alpha4beta2-like nAChRs are present on somatodendritic and/or preterminal/terminal regions of interneurons in the CA1 field of the rat hippocampus and in the human cerebral cortex and that activation of the different nAChR subtypes present in the preterminal/terminal areas of the interneurons triggers the tetrodotoxin-sensitive release of GABA. Modulation by nAChRs of GABAergic transmission, which can result either in inhibition or disinhibition of pyramidal neurons, depends both on the receptor subtype present in the interneurons and on the agonist acting upon these receptors. Not only do alpha7 nAChRs desensitize faster than alpha4beta2 nAChRs, but also alpha7 nAChR desensitization induced by ACh lasts longer than that induced by choline. These mechanisms, which appear to be retained across species, might explain the involvement of nAChRs in cognitive functions and in such neurological disorders as Alzheimer's disease and schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942040     DOI: 10.1016/s0166-4328(00)00208-4

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  28 in total

Review 1.  The effects of dietary choline.

Authors:  Elisabetta Biasi
Journal:  Neurosci Bull       Date:  2011-10       Impact factor: 5.203

2.  Sexually diergic, dose-dependent hypothalamic-pituitary-adrenal axis responses to nicotine in a dynamic in vitro perfusion system.

Authors:  Jessica M McKlveen; Jared M Wilson; Robert T Rubin; Michael E Rhodes
Journal:  J Pharmacol Toxicol Methods       Date:  2010-02-01       Impact factor: 1.950

3.  The influence of sensory afferent input on local motor cortical excitatory circuitry in humans.

Authors:  Robin F H Cash; Reina Isayama; Carolyn A Gunraj; Zhen Ni; Robert Chen
Journal:  J Physiol       Date:  2015-01-30       Impact factor: 5.182

4.  Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats.

Authors:  R B Gibbs; A M Chipman; R Hammond; D Nelson
Journal:  Horm Behav       Date:  2011-08-26       Impact factor: 3.587

5.  Differential effect of nicotinic agonists on the [3H]norepinephrine release from rat hippocampal slices.

Authors:  J P Kiss; K Windisch; K De Oliveira; E C Hennings; A Mike; B K Szász
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

Review 6.  α7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimum.

Authors:  Victor V Uteshev
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

7.  Immunohistochemical increase in cyclooxygenase-2 without apoptosis in different brain areas of subchronic nicotine- and D-amphetamine-treated rats.

Authors:  A Toledano; M I Alvarez; I Caballero; P Carmona; E De Miguel
Journal:  J Neural Transm (Vienna)       Date:  2008-03-20       Impact factor: 3.575

8.  AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors.

Authors:  Marja Van Kampen; Karin Selbach; Renate Schneider; Elleonore Schiegel; Frank Boess; Rudy Schreiber
Journal:  Psychopharmacology (Berl)       Date:  2004-01-15       Impact factor: 4.530

Review 9.  Clinical pharmacokinetics of galantamine.

Authors:  Martin R Farlow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

Authors:  Laura F Martin; William R Kem; Robert Freedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.